Company intelligence / Profile preview
AlaMab Therapeutics
Princeton, New Jersey, United Statesalamab.com ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
ALMB-0166 is in Phase 2 clinical trials for acute spinal cord injury, while ALMB-0168 is in Phase 1 for osteosarcoma. As of 2024, both drugs have received approval for first-in-human clinical trials in Australia. ALMB-0166 has been granted Orphan-Drug Designation by the U.S. FDA for acute spinal cord injury, and ALMB-0168 has received Rare Pediatric Disease Designation from the FDA.
- Therapeutic areas
- OncologyNeurology
- Modalities
- Monoclonal antibodiesAntibody therapeuticsFirst-in-class antibody drugs
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Partnerships
University of Texas
Beyond the preview
Go deeper on AlaMab Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AlaMab Therapeutics.